Holen Sie sich die Stockscreener-App
7.89
1.15%
0.09
Vorhandelsmarkt:
7.94
0.05
+0.63%
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
Is It Too Late To Consider Ardelyx (ARDX) After The Recent Share Price Surge? - simplywall.st
All You Need to Know About Ardelyx (ARDX) Rating Upgrade to Buy - Yahoo Finance
Palisades Investment Partners LLC Cuts Position in Ardelyx, Inc. $ARDX - MarketBeat
AIGH Capital Management LLC Makes New Investment in Ardelyx, Inc. $ARDX - MarketBeat
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Ardelyx (ARDX) and AxoGen (AXGN) - The Globe and Mail
Ardelyx Investors Appeal Dismissal of Medicare Program Lawsuit - Bloomberg Law News
Ardelyx responds to Zydus Lifesciences acquisition reports - CNBC TV18
Ardelyx stock hits 52-week high at 8.06 USD By Investing.com - Investing.com India
ZYDUS EYES ARDELYX ACQUISITION DEAL - ICICI Direct
Ardelyx: Assessment Of Acquisition Rumors (NASDAQ:ARDX) - Seeking Alpha
ARDX: Wedbush Raises Price Target to $19, Maintains Outperform R - GuruFocus
Ardelyx (NASDAQ:ARDX) Sets New 52-Week High on Analyst Upgrade - MarketBeat
Ardelyx stock hits 52-week high at 8.06 USD - Investing.com
Wedbush Increases Ardelyx (NASDAQ:ARDX) Price Target to $19.00 - MarketBeat
ARDX: Wedbush Raises Price Target to $19, Maintains Outperform Rating | ARDX Stock News - GuruFocus
Lam Research To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Demystifying Ardelyx: Insights From 7 Analyst Reviews - Benzinga
Ardelyx (ARDX) price target increased by 12.82% to 13.46 - MSN
Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength? - Nasdaq
Ardelyx, Inc. (NASDAQ:ARDX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry - simplywall.st
Zydus Gets World’s First Menkes Disease Drug Approval Amid Ardelyx Acquisition Speculation - Citeline News & Insights
Grapevine: Zydus in talks to acquire US biopharma firm; K Raheja mulls IPO - VCCircle
Wedbush Raises Ardelyx Price Target to $19 Amid Outperform Rating - Intellectia AI
Health Care Stocks Split As Deal Talk Lifts Select Names - Finimize
Zydus Lifesciences eyes $2.5 billion US biopharma buyout of Ardelyx: Report - Moneycontrol
Zydus Lifesciences plans to acquire Ardelyx for USD 2.5B - Medical Buyer
Ardelyx stock soars on report of potential Zydus Life acquisition By Investing.com - Investing.com South Africa
Ardelyx stock soars on report of potential Zydus Life acquisition - Investing.com
Ardelyx (NASDAQ:ARDX) Trading Up 10.2%Here's What Happened - MarketBeat
Ardelyx Shares Soar as Analysts Raise Price Targets - StocksToTrade
Ardelyx Stock Surges Amid Upgraded Ratings and Revenue Projections - timothysykes.com
Zydus Lifesciences eyes acquisition of US firm Ardelyx for $2.5 billion | Company Business News - Mint
Ardelyx (ARDX) Surges on Potential Acquisition by Zydus Lifesciences - GuruFocus
Ardelyx: IBSRELA Momentum Drives Opportunity (NASDAQ:ARDX) - Seeking Alpha
Zydus Life may acquire US-firm Ardelyx; may fund deal via QIP - India Infoline
Zydus Life to Acquire Ardelyx, Raise Funds via QIP; Shares Flat - Equitypandit
Zydus Lifesciences in talks to acquire US biopharma firm Ardelyx, may raise ₹5,000 crore via QIP - scanx.trade
Zydus Life may acquire US-firm Ardelyx, may raise funds via QIP to part-fund deal: Exclusive - CNBC TV18
Ardelyx stock rises premarket as Piper sees over 100% upside — says constipation drug 'stole the show' with 2026 guidance - MSN
Lobbying Update: $580,000 of ARDELYX INC. lobbying was just disclosed - Quiver Quantitative
Ardelyx says 2025 total product revenue was about $378M - MSN
Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Exit Recap: Can Ardelyx Inc continue delivering strong returns2025 Market Sentiment & Real-Time Volume Surge Alerts - baoquankhu1.vn
Insider Buy: Can Ardelyx Inc stock outperform in 2025 bull market2025 Biggest Moves & Consistent Income Trade Ideas - Bộ Nội Vụ
Ardelyx (ARDX) Price Target Increased by 12.82% to 13.46 - Nasdaq
Lobbying Update: $30,000 of ARDELYX INC. lobbying was just disclosed | ARDX Stock News - Quiver Quantitative
Ardelyx Stock Is Rallying – What Is Making Retail So Bullish? - Asianet Newsable
Ardelyx (NASDAQ:ARDX) Stock Price Down 6.8% on Insider Selling - MarketBeat
Are Medical Stocks Lagging Ardelyx (ARDX) This Year? - Yahoo Finance
Ardelyx Inc: Citigroup raises target price to $14 from $11 - marketscreener.com
Ardelyx chief patient officer Williams sells $348,900 in stock By Investing.com - Investing.com Australia
Top Ardelyx Executive Executes Significant Stock Sale That Investors Can’t Ignore - TipRanks
Ardelyx chief patient officer Williams sells $348,900 in stock - Investing.com India
Insider Selling: Ardelyx (NASDAQ:ARDX) Insider Sells 50,000 Shares of Stock - MarketBeat
Ardelyx’s Stock Ascends Following Strategic Upgrades and Promising Revenue Projections - StocksToTrade
Why Ardelyx (ARDX) Is Up 20.1% After Lawsuit Dismissal And Patent Extension For Tenapanor - simplywall.st
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):